Carlos Alberto Fermín-Martínez

Carlos Alberto Fermín-Martínez

Auto-generated profile, based on publicly available information

Carlos Alberto Fermín-Martínez

Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2020 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
JBJessica Paola Bahena-López
Jessica Paola Bahena-López
AVArsenio Vargas-Vázquez
Arsenio Vargas-Vázquez
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
AMAlejandro Márquez-Salinas
Alejandro Márquez-Salinas
TGthe Metabolic Syndrome Study Group
the Metabolic Syndrome Study Group
Introduction Previous reports in European populations demonstrated the existence of five data-driven adult-onset diabetes subgroups. Here, we use self-normalizing neural networks (SNNN) to improve reproducibility of these data-driven diabetes subgroups in Mexican cohorts to extend its application to more diverse settings. Research design and methods We trained SNNN and compared it with k-means clustering to classify diabetes subgroups in a multiethnic and representative population-based National Health and Nutrition Examination Survey (NHANES) datasets with all available measures (training sample: NHANES-III, n=1132; validation sample: NHANES 1999–2006, n=626). SNNN models were then applied to four Mexican cohorts (SIGMA-UIEM, n=1521; Metabolic Syndrome cohort, n=6144; ENSANUT 2016, n=614 and CAIPaDi, n=1608) to characterize diabetes subgroups in Mexicans according to treatment response, risk for chronic complications and risk factors for the incidence of each subgroup. Results SNNN yielded four reproducible clinical profiles (obesity related, insulin deficient, insulin resistant, age related) in NHANES and Mexican cohorts even without C-peptide measurements. We observed in a population-based survey a high prevalence of the insulin-deficient form (41.25%, 95% CI 41.02% to 41.48%), followed by obesity-related (33.60%, 95% CI 33.40% to 33.79%), age-related (14.72%, 95% CI 14.63% to 14.82%) and severe insulin-resistant groups. A significant association was found between the SLC16A11 diabetes risk variant and the obesity-related subgroup (OR 1.42, 95% CI 1.10 to 1.83, p=0.008). Among incident cases, we observed a greater incidence of mild obesity-related diabetes (n=149, 45.0%). In a diabetes outpatient clinic cohort, we observed increased 1-year risk (HR 1.59, 95% CI 1.01 to 2.51) and 2-year risk (HR 1.94, 95% CI 1.13 to 3.31) for incident retinopathy in the insulin-deficient group and decreased 2-year diabetic retinopathy risk for the obesity-related subgroup (HR 0.49, 95% CI 0.27 to 0.89). Conclusions Diabetes subgroup phenotypes are reproducible using SNNN; our algorithm is available as web-based tool. Application of these models allowed for better characterization of diabetes subgroups and risk factors in Mexicans that could have clinical applications.

12 July 2022 in BMJ
Verified
Journal Article
Open access
PDF file
VJValentijn de Jong
Valentijn de Jong
RRRebecca Z Rousset
Rebecca Z Rousset
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
ABArnoldus G Buenen
Arnoldus G Buenen
BCBen Van Calster
Ben Van Calster
TDThomas P. Debray
Thomas P. Debray
Objective: To externally validate various prognostic models and scoring rules for predicting short term mortality in patients admitted to hospital for covid-19. Design: Two stage individual participant data meta-analysis. Setting: Secondary and tertiary care. Participants: 46 914 patients across 18 countries, admitted to a hospital with polymerase chain reaction confirmed covid-19 from November 2019 to April 2021. Data sources: Multiple (clustered) cohorts in Brazil, Belgium, China, Czech Republic, Egypt, France, Iran, Israel, Italy, Mexico, Netherlands, Portugal, Russia, Saudi Arabia, Spain, Sweden, United Kingdom, and United States previously identified by a living systematic review of covid-19 prediction models published in The BMJ , and through PROSPERO, reference checking, and expert knowledge. Model selection and eligibility criteria: Prognostic models identified by the living systematic review and through contacting experts. A priori models were excluded that had a high risk of bias in the participant domain of PROBAST (prediction model study risk of bias assessment tool) or for which the applicability was deemed poor. Methods: Eight prognostic models with diverse predictors were identified and validated. A two stage individual participant data meta-analysis was performed of the estimated model concordance (C) statistic, calibration slope, calibration-in-the-large, and observed to expected ratio (O:E) across the included clusters. Main outcome measures: 30 day mortality or in-hospital mortality. Results: Datasets included 27 clusters from 18 different countries and contained data on 46 914patients. The pooled estimates ranged from 0.67 to 0.80 (C statistic), 0.22 to 1.22 (calibration slope), and 0.18 to 2.59 (O:E ratio) and were prone to substantial between study heterogeneity. The 4C Mortality Score by Knight et al (pooled C statistic 0.80, 95% confidence interval 0.75 to 0.84, 95% prediction interval 0.72 to 0.86) and clinical model by Wang et al (0.77, 0.73 to 0.80, 0.63 to 0.87) had the highest discriminative ability. On average, 29% fewer deaths were observed than predicted by the 4C Mortality Score (pooled O:E 0.71, 95% confidence interval 0.45 to 1.11, 95% prediction interval 0.21 to 2.39), 35% fewer than predicted by the Wang clinical model (0.65, 0.52 to 0.82, 0.23 to 1.89), and 4% fewer than predicted by Xie et al’s model (0.96, 0.59 to 1.55, 0.21 to 4.28). Conclusion: The prognostic value of the included models varied greatly between the data sources. Although the Knight 4C Mortality Score and Wang clinical model appeared most promising, recalibration (intercept and slope updates) is needed before implementation in routine care.

1 February 2021 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
AVArsenio Vargas-Vázquez
Arsenio Vargas-Vázquez
RMRoopa Mehta
Roopa Mehta
CFCarlos A. Fermín-Martínez
Carlos A. Fermín-Martínez
RRRosalba Rojas
Rosalba Rojas

24 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
JBJessica Paola Bahena-López
Jessica Paola Bahena-López
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
AVArsenio Vargas-Vázquez
Arsenio Vargas-Vázquez
AGArmando González-Díaz
Armando González-Díaz
CACarlos A. Aguilar-Salinas
Carlos A. Aguilar-Salinas
BACKGROUND: The SARS-CoV-2 outbreak poses challenge to healthcare systems due to high complication rates in patients with cardiometabolic diseases. Here, we identify risk factors and propose a clinical score to predict COVID-19 lethality, including specific factors for diabetes and obesity and its role in improving risk prediction. METHODS: We obtained data of confirmed and negative COVID-19 cases and their demographic and health characteristics from the General Directorate of Epidemiology of Mexican Ministry of Health. We investigated specific risk factors associated to COVID-19 positivity and mortality and explored the impact of diabetes and obesity on modifying COVID-19 related lethality. Finally, we built a clinical score to predict COVID-19 lethality. RESULTS: Among 177,133 subjects at May 18 th , 2020, we observed 51,633 subjects with SARS-CoV-2 and 5,332 deaths. Risk factors for lethality in COVID-19 include early-onset diabetes, obesity, COPD, advanced age, hypertension, immunosuppression, and CKD; we observed that obesity mediates 49.5% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes conferred an increased risk of hospitalization and obesity conferred an increased risk for ICU admission and intubation. Our predictive score for COVID-19 lethality included age ≥65 years, diabetes, early-onset diabetes, obesity, age <40 years, CKD, hypertension, and immunosuppression and significantly discriminates lethal from non-lethal COVID-19 cases (c-statistic=0.823). RESULTS: Here, we propose a mechanistic approach to evaluate risk for complications and lethality attributable to COVID-19 considering the effect of obesity and diabetes in Mexico. Our score offers a clinical tool for quick determination of high-risk susceptibility patients in a first contact scenario.

29 September 2022 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
CFCarlos A Fermín-Martínez
Carlos A Fermín-Martínez
JAJose Manuel Aburto
Jose Manuel Aburto
LFLuisa Fernández-Chirino
Luisa Fernández-Chirino
JSJacqueline Seiglie
Jacqueline Seiglie
Background: In 2020, Mexico experienced one of the highest rates of excess mortality globally. However, the extent of non-COVID deaths on excess mortality, its regional distribution and the association between socio-demographic inequalities have not been characterized. Methods: We conducted a retrospective municipal and individual-level study using 1 069 174 death certificates to analyse COVID-19 and non-COVID-19 deaths classified by ICD-10 codes. Excess mortality was estimated as the increase in cause-specific mortality in 2020 compared with the average of 2015–2019, disaggregated by primary cause of death, death setting (in-hospital and out-of-hospital) and geographical location. Correlates of individual and municipal non-COVID-19 mortality were assessed using mixed effects logistic regression and negative binomial regression models, respectively. Results: We identified a 51% higher mortality rate (276.11 deaths per 100 000 inhabitants) compared with the 2015–2019 average period, largely attributable to COVID-19. Non-COVID-19 causes comprised one-fifth of excess deaths, with acute myocardial infarction and type 2 diabetes as the two leading non-COVID-19 causes of excess mortality. COVID-19 deaths occurred primarily in-hospital, whereas excess non-COVID-19 deaths occurred in out-of-hospital settings. Municipal-level predictors of non-COVID-19 excess mortality included levels of social security coverage, higher rates of COVID-19 hospitalization and social marginalization. At the individual level, lower educational attainment, blue-collar employment and lack of medical care assistance prior to death were associated with non-COVID-19 deaths. Conclusion: Non-COVID-19 causes of death, largely chronic cardiometabolic conditions, comprised up to one-fifth of excess deaths in Mexico during 2020. Non-COVID-19 excess deaths occurred disproportionately out-of-hospital and were associated with both individual- and municipal-level socio-demographic inequalities.

23 October 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
LFLuisa Fernández-Chirino
Luisa Fernández-Chirino
AVArsenio Vargas-Vázquez
Arsenio Vargas-Vázquez
CFCarlos A Fermín-Martínez
Carlos A Fermín-Martínez
CACarlos A. Aguilar-Salinas
Carlos A. Aguilar-Salinas
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
Context: Data-driven diabetes subgroups were proposed as an alternative to address diabetes heterogeneity. However, changes in trends for these subgroups have not been reported.Objective: Here, we analyzed trends of diabetes subgroups, stratified by sex, race, education level, age categories, and time since diabetes diagnosis in the United States.Methods: We used data from consecutive NHANES cycles spanning the 1988-2018 period. Diabetes subgroups (mild obesity-related [MOD], severe insulin-deficient [SIDD], severe insulin-resistant [SIRD], and mild age-related diabetes [MARD]) were classified using validated self-normalizing neural networks. Severe autoimmune diabetes (SAID) was assessed for NHANES-III. Prevalence was estimated using examination sample weights considering bicyclic changes (BCs) to evaluate trends and changes over time.Results: Diabetes prevalence in the United States increased from 7.5% (95% CI 7.1-7.9) in 1988-1989 to 13.9% (95% CI 13.4-14.4) in 2016-2018 (BC 1.09%, 95% CI 0.98-1.31, P < .001). Non-Hispanic Black people had the highest prevalence. Overall, MOD, MARD, and SIDD had an increase during the studied period. Particularly, non-Hispanic Black people had sharp increases in MARD and SIDD, Mexican Americans in SIDD, and non-Hispanic White people in MARD. Males, subjects with secondary/high school, and adults aged 40-64 years had the highest increase in MOD prevalence. Trends in diabetes subgroups sustained after stratifying time since diabetes diagnosis.Conclusion: Prevalence of diabetes and its subgroups in the United States has increased from 1988 to 2018. These trends were different across sex, ethnicities, education, and age categories, indicating significant heterogeneity in diabetes within the US obesity burden, population aging, socioeconomic disparities, and lifestyle aspects could be implicated in the increasing trends of diabetes in the United States.